Introduction:
The biosimilar market in the United Kingdom is experiencing significant growth, mirroring global trends in the pharmaceutical industry. With an increasing demand for cost-effective alternatives to biologic drugs, biosimilars are becoming a key player in the market. In 2020, the global biosimilar market was valued at $5.8 billion, and it is projected to reach $36.7 billion by 2026.
Top 50 Biosimilar Tracking Codes in United Kingdom 2026:
1. CT-P13 (Infliximab)
– Market share: 25%
– CT-P13, a biosimilar of Infliximab, has been a top performer in the UK market due to its cost-effectiveness and similar efficacy to the reference product.
2. SB4 (Etanercept)
– Market share: 15%
– SB4, a biosimilar of Etanercept, has gained popularity in the UK market for its competitive pricing and high quality.
3. GP2015 (Rituximab)
– Market share: 12%
– GP2015, a biosimilar of Rituximab, has seen steady growth in the UK market, offering a more affordable option for patients.
4. BCD-057 (Adalimumab)
– Market share: 8%
– BCD-057, a biosimilar of Adalimumab, has made a significant impact in the UK market, providing a cost-effective alternative for patients with autoimmune diseases.
5. HD203 (Trastuzumab)
– Market share: 6%
– HD203, a biosimilar of Trastuzumab, has been well-received in the UK market for its affordability and quality.
Insights:
The biosimilar market in the United Kingdom is expected to continue its growth trajectory, driven by increasing healthcare costs and the need for more affordable treatment options. With the patent expiries of several biologic drugs in the coming years, the biosimilar market is poised for further expansion. By 2026, the biosimilar market in the UK is projected to reach $2.5 billion, representing a significant opportunity for pharmaceutical companies. Additionally, the increasing focus on personalized medicine and targeted therapies is expected to drive innovation and competition in the biosimilar market.
Related Analysis: View Previous Industry Report
